elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate) (Stribild)

in the absence of a submission from the holder of the marketing authorisation

elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (as fumarate) (Stribild®) is not recommended for use within NHSScotland.

Indication under review: Treatment of HIV-1 infection in adolescents aged 12 to <18 years weighing ≥35kg who are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

______________________________________________________________________________________

From January 2020, ADTCs may make formulary decisions on paediatric licence extensions for medicines previously accepted for use (or restricted use) for the corresponding indication in adults, taking account of relevant restrictions. This approach may also be applied retrospectively to medicines accepted for use in adults but not recommended in the corresponding indication in children due to absence of submission. PASAG liaises with companies to extend any PAS to include the younger age group and confirms arrangements with Boards.